{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:02:35Z","timestamp":1793325755471,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jiac.2026.103042","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:26:02Z","timestamp":1785194762000},"page":"103042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Concentration-dependent suppression of macrolide resistance in Mycobacterium avium by combination therapy: An improved in vitro time-kill assay and alveolar macrophage exposure-based pharmacokinetic\/pharmacodynamic modeling study"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5272-2249","authenticated-orcid":false,"given":"Fumiya","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3818-5288","authenticated-orcid":false,"given":"Yuta","family":"Morishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-6892","authenticated-orcid":false,"given":"Akio","family":"Aono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1371-8591","authenticated-orcid":false,"given":"Yuji","family":"Morita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-077X","authenticated-orcid":false,"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9041-5589","authenticated-orcid":false,"given":"Kazuhiko","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2026.103042_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jiac.2026.103042_bib2","series-title":"Clinical and laboratory standards institute. M24","year":"2018"},{"key":"10.1016\/j.jiac.2026.103042_bib3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.200603-450OC","article-title":"Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease","volume":"174","author":"Griffith","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2026.103042_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106025","article-title":"Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy","volume":"169","author":"Ito","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2026.103042_bib5","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1513\/AnnalsATS.201604-246OC","article-title":"Macrolide-resistant Mycobacterium avium complex lung disease: analysis of 102 consecutive cases","volume":"13","author":"Morimoto","year":"2016","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jiac.2026.103042_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2026.103042_bib7","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1378\/chest.15-0543","article-title":"Long-term follow-up of Mycobacterium avium complex lung disease in patients treated with regimens including clofazimine and\/or rifampin","volume":"149","author":"Jarand","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2026.103042_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.chest.2023.11.038","article-title":"Safety and efficacy of clofazimine as an alternative for rifampicin in Mycobacterium avium complex pulmonary disease treatment: outcomes of a randomized trial","volume":"165","author":"Zweijpfenning","year":"2024","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2026.103042_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12890-022-02063-2","article-title":"Old age is associated with worse treatment outcome and frequent adverse drug reaction in Mycobacterium avium complex pulmonary disease","volume":"22","author":"Kim","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jiac.2026.103042_bib10","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.5588\/ijtld.14.0139","article-title":"Determinants of recurrence after successful treatment of Mycobacterium avium complex lung disease","volume":"19","author":"Min","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.jiac.2026.103042_bib11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1513\/AnnalsATS.202412-1307OC","article-title":"Adverse drug reactions during nontuberculous mycobacterial pulmonary disease treatment: a systematic review and meta-analysis","volume":"23","author":"Kim","year":"2026","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jiac.2026.103042_bib12","first-page":"879","article-title":"Low-dosage ethambutol, less than 12.5 mg\/kg\/day, does not worsen the clinical outcomes of pulmonary Mycobacterium avium and Mycobacterium intracellulare disease: a retrospective cohort study","volume":"50","author":"Watanabe","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.jiac.2026.103042_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.25259\/IJMR_1673_2024","article-title":"Efficacy & safety of high-dose rifampicin in pulmonary tuberculosis: a systematic review & meta-analysis","volume":"161","author":"Kannabiran","year":"2025","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.jiac.2026.103042_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2026.108708","article-title":"Amikacin exposure and its association with ototoxicity and efficacy in nontuberculous mycobacterial pulmonary disease treatment","volume":"253","author":"Watanabe","year":"2026","journal-title":"Respir Med"},{"key":"10.1016\/j.jiac.2026.103042_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102823","article-title":"Clinical considerations of the safety and efficacy of clofazimine in the treatment of nontuberculous mycobacterial disease","volume":"31","author":"Watanabe","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib16","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/11594090-000000000-00000","article-title":"Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents","volume":"50","author":"Rodvold","year":"2011","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jiac.2026.103042_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3390\/pharmaceutics11070352","article-title":"Inhaled antibiotics for mycobacterial lung disease","volume":"11","author":"Banaschewski","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jiac.2026.103042_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00133-06","article-title":"Interpretation of antibiotic concentration ratios measured in epithelial lining fluid","volume":"52","author":"Kiem","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02730-20","article-title":"An in vitro perspective on what individual antimicrobials add to Mycobacterium avium complex therapies","volume":"65","author":"Sonawane","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68248-3","article-title":"Pharmacokinetics of anti-Mycobacterium avium-intracellulare disease drugs in silkworms","volume":"14","author":"Watanabe","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jiac.2026.103042_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1016\/j.jiac.2026.103042_bib22","first-page":"37","article-title":"Postantibiotic effects of rifampin, amikacin, clarithromycin and ethambutol used alone or in various two-, three- and four-drug combinations against Mycobacterium avium","volume":"23","author":"Horgen","year":"1999","journal-title":"FEMS Immunol Med Microbiol"},{"key":"10.1016\/j.jiac.2026.103042_bib23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jac\/40.1.33","article-title":"Evaluation of the post-antibiotic effect of six anti-mycobacterial agents against Mycobacterium avium by the Bactec radiometric method","volume":"40","author":"Fuursted","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112084","article-title":"Drug resistance reversal potential of multifunctional thieno[3,2-c]pyran via potentiation of antibiotics in MDR P. aeruginosa","volume":"142","author":"Dwivedi","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jiac.2026.103042_bib25","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.40.11.2582","article-title":"Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses","volume":"40","author":"Olsen","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib26","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1128\/AAC.41.6.1399","article-title":"Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers","volume":"41","author":"Rodvold","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib27","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1378\/chest.125.3.965","article-title":"Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults","volume":"125","author":"Capitano","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.jiac.2026.103042_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1062963","article-title":"Mycobacterium tuberculosis-macrophage interaction: molecular updates","volume":"13","author":"Bo","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.jiac.2026.103042_bib29","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1128\/AAC.35.8.1677","article-title":"Effect of pH on the in vitro potency of clarithromycin against Mycobacterium avium complex","volume":"35","author":"Truffot-Pernot","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201204-0682OC","article-title":"The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment","volume":"186","author":"Van Ingen","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jiac.2026.103042_bib31","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00218-24","article-title":"Minimum inhibitory concentrations of azithromycin in clinical isolates of Mycobacterium avium complex in Japan","volume":"12","author":"Uwamino","year":"2024","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jiac.2026.103042_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00491-18","article-title":"In vitro MIC values of rifampin and ethambutol and treatment outcome in Mycobacterium avium complex lung disease","volume":"62","author":"Kwon","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib33","doi-asserted-by":"crossref","first-page":"e3365","DOI":"10.1093\/cid\/ciaa1265","article-title":"Intrapulmonary pharmacokinetics of first-line anti-tuberculosis drugs in Malawian patients with tuberculosis","volume":"73","author":"McCallum","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2026.103042_bib34","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria \u2013 determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jiac.2026.103042_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2022.106219","article-title":"Amikacin pharmacokinetics in elderly patients with severe infections","volume":"175","author":"Medell\u00edn-Garibay","year":"2022","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.jiac.2026.103042_bib36","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01393-23","article-title":"Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics","volume":"68","author":"Shin","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib37","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib38","doi-asserted-by":"crossref","unstructured":"Watanabe F, Hiramatsu M, Kawakami T, Oka T, Nanami H, Shimoda K et al. Pulmonary distribution and lesion penetration of antimicrobials in patients with nontuberculous mycobacterial disease. medRxiv. https:\/\/doi.org\/10.64898\/2026.05.12.26352725 [preprint].","DOI":"10.64898\/2026.05.12.26352725"},{"key":"10.1016\/j.jiac.2026.103042_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/psp4.12052","article-title":"A tutorial on RxODE: simulating differential equation pharmacometric models in R","volume":"5","author":"Wang","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.jiac.2026.103042_bib40","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1128\/AAC.49.6.2387-2398.2005","article-title":"Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination","volume":"49","author":"Bakker-Woudenberg","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"Supplement 3","key":"10.1016\/j.jiac.2026.103042_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/1120009X.2004.11782371","article-title":"The role of PK\/PD parameters to avoid selection and increase of resistance: mutant prevention concentration","volume":"16","author":"Blondeau","year":"2004","journal-title":"J Chemother"},{"key":"10.1016\/j.jiac.2026.103042_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiph.2025.102711","article-title":"Two-drug versus three-drug regimens for treating Mycobacterium avium complex infection: a systematic review and meta-analysis","volume":"18","author":"Nguyen","year":"2025","journal-title":"J Infect Public Health"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X26001406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:42:31Z","timestamp":1787053351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X26001406"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1341321X26001406"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103042","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concentration-dependent suppression of macrolide resistance in Mycobacterium avium by combination therapy: An improved in vitro time-kill assay and alveolar macrophage exposure-based pharmacokinetic\/pharmacodynamic modeling study","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2026.103042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103042"}}